^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Nimotuzumab, an EGFR-targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma

Published date:
04/23/2020
Excerpt:
These results suggest that nimotuzumab combined with radiation may be an effective means to control recurrent esophageal squamous cell carcinoma with EGFR overexpression.
DOI:
10.3892/ijo.2020.4981